Press release
published
28 Oct
by Carlson Investments SE
The company’s compact PCR.smart platform — enabling real-time molecular diagnostics directly at the point of sample collection — has drawn growing attention from the food safety, veterinary, and agricultural sectors. In recent months, Bioaccure has presented its solutions to distributors and practitioners at leading industry events, receiving strong validation from end users impressed by the platform’s versatility and performance.
After securing a Polish patent for the core of its PCR.smart technology, Bioaccure has now been granted a US patent, with its EU application in final review. In parallel, the company has filed two new international patent applications, one covering a globally unique proprietary test for food safety applications. With new patents secured, commercialization underway, and growing international interest, Bioaccure is entering a decisive stage of development. Bioaccure CEO Aleksander Sienkiewicz shares:
“It is a wonderful feeling when, during discussions with our market partners, both on the distribution side and among subcontractors, we continue to experience their surprise at how innovative and unique our diagnostic platform is.”
About Bioaccure
Bioaccure is a molecular diagnostics innovator specializing in real-time PCR platforms for field and industrial use. Its patented PCR.smart system combines portability, accuracy, and speed to deliver lab-quality results in agriculture, veterinary medicine, and food safety applications.
About Carlson Investments SE
Carlson Investments SE, listed on Warsaw’s NewConnect and the German Open Market (Frankfurt, Munich, Stuttgart, Gettex), supports high-growth early-stage tech ventures across healthtech, AI, fintech, and deeptech. Carlson applies a hands-on investment approach and integrates its portfolio companies into a global network of strategic partnerships.
Risk Disclaimer
This announcement • does not constitute investment advice or a solicitation to buy or sell financial instruments • involves risks, including possible loss of capital • does not guarantee future earnings • past performance is not indicative of future results.
WE ARE PUBLICLY LISTED, YOU CAN BUY OUR SHARES ON:
Warsaw Stock Exchange (PLN): CAI, PLHOTB000011
Frankfurt Stock Exchange (EUR): 2HB (FRA), PLHOTB000011
Munich Stock Exchange (EUR): 2HB (MUN), PLHOTB000011
Stuttgart Stock Exchange (EUR): 2HB (STU), PLHOTB000011
GETTEX Exchange (EUR): 2HB (GET), PLHOTB000011
WKN: A0RNWQ
Press Contact:
Management Office
Carlson Investments SE
ir@carlsonvc.com
www.carlsonvc.com
ir@carlsonvc.com
Category : Business, Finance, Employment & Investment
Tags : Venture Capital, Startups, EU Startups, Polish Startups, Bioaccure, Carlson Investments SE, Veterinary, Agriculture
###
All the content in published press releases at Viral Press Releases is written and submitted by the press release author.
Viral Press Releases DO NOT accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in any published press release on viralpressreleases.com
If you have any question regarding some information in a press release, please contact the person listed in 'Media Contacts ' at the bottom of press release page.
Please DO NOT attempt to contact Viral Press Releases. We will be unable to assist you with any information regarding any published press release on Viral Press Releases.
Viral Press Releases disclaims any content contained in any published press release on Viral Press Releases.